Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its project to advance a robotic aseptic fill-and-finish platform has been approved for expanded support by the Israel Innovation Authority. The approval allows the company to utilize the full approved grant budget of NIS 5 million over two years, with approximately 66% representing non-dilutive funding.
The program supports acquisition and validation of a fully automated robotic-arm aseptic fill-and-finish system aligned with EU GMP Annex 1 standards. Validation is targeted for completion by the third quarter of 2026. This investment supports Scinai’s broader contract development and manufacturing organization expansion strategy following its acquisition of Recipharm Israel Ltd. and commercial collaboration with Recipharm.
The robotic platform strengthens Scinai’s integrated two-site manufacturing platform and enhances sterile biologics capabilities while maintaining disciplined capital allocation through maximized non-dilutive funding. Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm’s global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance.
Scinai’s CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies, operating two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne. The CDMO supports external clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization.
In parallel with its CDMO operations, Scinai is advancing a focused immunology pipeline through its R&D unit, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation. Additional information about the company is available through its newsroom at https://ibn.fm/SCNI.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Scinai Immunotherapeutics Secures Expanded IIA Grant for Robotic Aseptic Manufacturing Platform.